On November 22, Wanbangde Pharmaceutical Holding Group (002082.SZ) stated at the investor event that the fluctuation in performance was mainly affected by centralized volume procurement of products, especially when the company's core product, ginkgo leaf capsules, was impacted by the centralized volume procurement, leading to a significant price reduction of about 54%, affecting the company's revenue and profit situation. As the regional and normalized implementation of centralized procurement policies gradually expands and stabilizes in the medical and pharmaceutical sectors, the company actively adjusts its marketing strategy to digest the pressure brought by centralized procurement. Currently, there is growth in ginkgo leaf capsule OTC channels and third-party terminals, as well as growth in products such as trimethobenzamide injections and new bromhexine products. After the high-molecular-weight products in the medical instruments sector were awarded centralized procurement bids, market share further expanded, leading to increased sales and a significant increase in revenue compared to the previous year; at the same time, the company optimized its operation system in South Africa, striving to increase market share in various medical instrument aspects such as diagnostic imaging, surgical instruments, and patient monitoring systems, achieving further revenue growth in the South African sector.